泰華天然生(sheng)(sheng)物制(zhi)藥有限公(gong)司成立于(yu)(yu)1993年，是一家集(ji)藥源種植基(ji)地(di)(di)、原料藥和中(zhong)成藥的生(sheng)(sheng)產、銷售為(wei)一體(ti)的現代化高新制(zhi)藥企業。公(gong)司生(sheng)(sheng)產基(ji)地(di)(di)位于(yu)(yu)素有“天然藥物寶(bao)庫”之稱(cheng)的秦(qin)嶺南(nan)麓陜西省商洛市洛南(nan)縣，總(zong)用地(di)(di)面積兩萬(wan)余平米。
公(gong)司(si)(si)現設(she)有藥(yao)(yao)(yao)源(yuan)(yuan)種(zhong)植(zhi)基(ji)地(di)(di)(di)、生(sheng)產(chan)基(ji)地(di)(di)(di)、中(zhong)成藥(yao)(yao)(yao)營銷(xiao)中(zhong)心、原料(liao)(liao)(liao)藥(yao)(yao)(yao)海外(wai)營銷(xiao)中(zhong)心四個事業部，生(sheng)產(chan)藥(yao)(yao)(yao)品涵蓋了腫瘤(liu)(liu)科(ke)(ke)、消化(hua)科(ke)(ke)、婦科(ke)(ke)、皮(pi)膚科(ke)(ke)等(deng)多個領域。原料(liao)(liao)(liao)藥(yao)(yao)(yao)海外(wai)營銷(xiao)中(zhong)心以高(gao)三尖杉酯堿、紫杉醇等(deng)抗腫瘤(liu)(liu)原料(liao)(liao)(liao)藥(yao)(yao)(yao)為核心，產(chan)品主要(yao)銷(xiao)往歐盟、以色列(lie)、俄羅斯、韓國(guo)(guo)等(deng)發(fa)達國(guo)(guo)家和(he)(he)地(di)(di)(di)區(qu)，受到境外(wai)客戶的高(gao)度(du)贊譽和(he)(he)支持(chi)；中(zhong)成藥(yao)(yao)(yao)營銷(xiao)中(zhong)心以便通片、芪棗顆粒、棗仁安神顆粒、杜仲(zhong)平壓片等(deng)內科(ke)(ke)用藥(yao)(yao)(yao)為龍頭，銷(xiao)售網(wang)絡覆蓋全國(guo)(guo)各個省份，并(bing)且獲得廣大(da)患(huan)者的一致好評和(he)(he)信賴；藥(yao)(yao)(yao)源(yuan)(yuan)種(zhong)植(zhi)基(ji)地(di)(di)(di)主要(yao)負責公(gong)司(si)(si)自(zi)有產(chan)品原藥(yao)(yao)(yao)材(cai)基(ji)地(di)(di)(di)建設(she)與供給，現有原料(liao)(liao)(liao)藥(yao)(yao)(yao)種(zhong)植(zhi)基(ji)地(di)(di)(di)3000余畝，主要(yao)植(zhi)株為曼迪(di)亞(ya)紅(hong)豆杉和(he)(he)中(zhong)國(guo)(guo)粗榧，為公(gong)司(si)(si)原料(liao)(liao)(liao)藥(yao)(yao)(yao)紫杉醇和(he)(he)高(gao)三尖杉酯堿提(ti)供了優質(zhi)的天(tian)然(ran)原料(liao)(liao)(liao)，同時科(ke)(ke)學利用土地(di)(di)(di)資源(yuan)(yuan)，在(zai)基(ji)地(di)(di)(di)共(gong)種(zhong)植(zhi)連翹、杜仲(zhong)、苦參等(deng)藥(yao)(yao)(yao)材(cai)數十(shi)萬株。除此之外(wai)，公(gong)司(si)(si)在(zai)秦嶺(ling)儲備(bei)林(lin)地(di)(di)(di)一萬余畝，并(bing)逐(zhu)步推(tui)進中(zhong)藥(yao)(yao)(yao)材(cai)生(sheng)態種(zhong)植(zhi)和(he)(he)野生(sheng)撫育計劃，在(zai)加強中(zhong)藥(yao)(yao)(yao)材(cai)道地(di)(di)(di)產(chan)區(qu)環境保護的同時，為大(da)家提(ti)供療效(xiao)更為突(tu)出的優質(zhi)天(tian)然(ran)藥(yao)(yao)(yao)材(cai)。
公司(si)生(sheng)(sheng)(sheng)產線已(yi)全部通過國家新版(ban)GMP認證，中(zhong)藥飲(yin)片、配方顆粒、保健食品(pin)事業(ye)(ye)部已(yi)處于籌建(jian)中(zhong)，預(yu)(yu)計2020年將(jiang)實現各個板(ban)塊(kuai)的投產。公司(si)還(huan)將(jiang)在傳統(tong)的原料藥和中(zhong)成藥基(ji)礎上(shang)，加大(da)藥物(wu)(wu)的科研(yan)(yan)力度，并從植物(wu)(wu)單體開(kai)發、化學藥物(wu)(wu)合成及成藥衍(yan)生(sheng)(sheng)(sheng)物(wu)(wu)的科學研(yan)(yan)發做(zuo)出更(geng)(geng)多的努力。預(yu)(yu)計2025年，泰華制藥將(jiang)實現以種植、生(sheng)(sheng)(sheng)產、研(yan)(yan)發、銷售(shou)為(wei)一體的完整(zheng)產業(ye)(ye)鏈覆蓋，屆時(shi)泰華醫(yi)藥健康產業(ye)(ye)將(jiang)發力，為(wei)社會(hui)和患者提供(gong)更(geng)(geng)豐富的產品(pin)、更(geng)(geng)優(you)質的服務。
買購網APP
手機版Maigoo
藥品
